论文部分内容阅读
目的 观察拉米夫定 (Lamivudine)对肝炎病毒 (HBV)感染者的疗效及安全性。方法 2 3 7例HBV感染者随机分为两组 ,治疗组 12 8例用拉米夫定每日 15 0mg治疗 48W ,对照组 10 9例常规保肝治疗。治疗第 8、16、2 4、48周分别检测HBVM、HBVDLT半定量、ALT等。结果 治疗组第 8、16、2 4、48周HBVDNA阴转率分别为 5 2 3 %、82 0 %、96 1%、89 1%均高于对照组 (P <0 0 5 ) ;治疗组HBeAg阴转率分别为 7 0 %、2 8 9%、71 9%、66 4%,后 3者高于对照组 (P <0 0 5 ) ;ALT复常率在第 8、16、48w分别为89 1%、97 7%、98 4%,后者高于对照组 (P <0 0 5 )。治疗组未发现明显拉米夫定相关性严重不良反应。结论 拉米夫定可有效降低患者血清HBVDNA水平 ,明显提高HBeAg阴转率 ,使ALT恢复正常 ,副反应轻而安全
Objective To observe the efficacy and safety of Lamivudine against hepatitis B virus (HBV) infection. Methods Twenty-seven cases of HBV infection were randomly divided into two groups. In the treatment group, 128 cases were treated with lamivudine daily for 15 days at 48W, while in the control group, 109 cases were treated routinely. HBVM, HBVDLT semi-quantitative and ALT were detected on the 8th, 16th, the 2nd, the 44th and the 48th week respectively. Results The negative rate of HBVDNA at the 8th, 16th, the 4th and the 448th weeks in the treatment group was 52.3%, 82.0%, 96.1% and 89.1%, respectively, compared with the control group (P <0.05) The negative conversion rate of HBeAg was 70.0%, 29.9%, 71.9% and 66.4% respectively, while the latter three were higher than the control group (P <0.05) 89 1%, 97 7% and 98 4%, respectively. The latter was higher than that of the control group (P <0.05). The treatment group did not find significant lamivudine-related serious adverse reactions. Conclusions Lamivudine can effectively reduce the level of serum HBV DNA, significantly improve the rate of HBeAg negative conversion, make ALT return to normal, mild and safe side effects